[Development of oral therapies for multiple sclerosis--fingolimod, cladribine and other drugs].
Orally disposable drugs for the treatment of multiple sclerosis have been research topics for long-term. Actually there are several drugs in clinical trial. Their mode of action differs among themselves and from established therapeutic agents. While cladribine acts as an antimetabolite and reduces lymphocytopoiesis, fingolimod influences circulation of lymphocytes. Fampridine alleviates symptoms by blocking potassium-channels. These and other drugs which are currently examined for oral administration are presented. The main focus is on the mode of action of these new drugs, in addition important results of clinical trials are summarized.
Hecht
Birgit
B
bhecht@wissenschaftliche-verlagsgesellschaft.de
D017338:Cladribine / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D000068876:Fingolimod Hydrochloride; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D009103:Multiple Sclerosis / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D011409:Propylene Glycols / Q000627:therapeutic use*; D013110:Sphingosine / Q000031:analogs & derivatives* / Q000627:therapeutic use
D007166:Immunosuppressive Agents; D011409:Propylene Glycols; D017338:Cladribine; D000068876:Fingolimod Hydrochloride; D013110:Sphingosine